EMEA-001072-PIP01-10-M04
Key facts
| Invented name |
Lemtrada
|
| Active substance |
alemtuzumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0269/2020
|
| PIP number |
EMEA-001072-PIP01-10-M04
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of multiple sclerosis
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Genzyme Europe B.V.
Tel: +49 (0) 800 52 52 010 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|